Nuance Investments LLC Has $111.55 Million Stake in QIAGEN N.V. (NYSE:QGEN)

Key Points

• Nuance Investments LLC reduced its stake in QIAGEN N.V. by 33%, selling 1,366,663 shares, which now represent 7.3% of its portfolio, making it the firm's third-largest position.
• QIAGEN reported $0.60 earnings per share for the last quarter, matching consensus expectations, and achieved a revenue of $533.54 million, up 7.7% from the previous year.
• The firm declared a dividend of $0.25 per share, with a dividend yield of 52.0%, and an ex-dividend date of July 2nd.

Nuance Investments LLC decreased its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 33.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,778,349 shares of the company's stock after selling 1,366,663 shares during the period. QIAGEN makes up about 7.3% of Nuance Investments LLC's holdings, making the stock its 3rd largest holding. Nuance Investments LLC owned 1.25% of QIAGEN worth $111,551,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in QGEN. Deutsche Bank AG lifted its stake in QIAGEN by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the last quarter. Earnest Partners LLC lifted its stake in QIAGEN by 1.6% during the fourth quarter. Earnest Partners LLC now owns 4,002,489 shares of the company's stock worth $178,231,000 after purchasing an additional 64,575 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in QIAGEN by 4.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after purchasing an additional 109,481 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in QIAGEN during the fourth quarter worth about $95,746,000. Finally, Barclays PLC lifted its stake in QIAGEN by 0.5% during the fourth quarter. Barclays PLC now owns 1,858,711 shares of the company's stock worth $82,767,000 after purchasing an additional 9,707 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

QIAGEN Trading Up 0.6%

QGEN traded up $0.28 during midday trading on Wednesday, reaching $49.25. 929,116 shares of the company's stock traded hands, compared to its average volume of 1,589,371. The firm has a fifty day moving average of $48.22 and a two-hundred day moving average of $43.64. The stock has a market capitalization of $10.95 billion, a price-to-earnings ratio of 29.10, a P/E/G ratio of 2.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%. The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same quarter in the prior year, the company posted $0.55 EPS. QIAGEN's quarterly revenue was up 7.7% compared to the same quarter last year. On average, equities analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current fiscal year.

QIAGEN Announces Dividend

The company also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 52.0%. QIAGEN's dividend payout ratio is 14.79%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Cowen reaffirmed a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday. UBS Group boosted their target price on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Robert W. Baird boosted their target price on QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Bank of America boosted their target price on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $49.69.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.